Antibodies against glioma biomarkers
The present disclosure is directed to antibodies binding to ELTDI. Plexin-B2, Spondin-1, fibulin-1, LINGO I or SLIT3 and methods of using such antibodies to treat and/or diagnose gliomas. Thus, in accordance with the present disclosure, there is provided a method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTDI, Plexin-B2, Spondin-1 or SLIT3. The method may further comprise contacting said glioma cell with a second anti-cancer agent or treatment.
1. A method of inhibiting a glioma cell comprising contacting said glioma cell with a first antibody or antibody fragment that binds immunologically to ELTD1, Spondin-1 or SLIT3.
2. The method of claim 1 , further comprising contacting said glioma cell with a second anti-cancer agent or treatment.
3. The method of claim 2 , wherein said second anti-cancer agent or treatment is selected from chemotherapy, radiotherapy, immunotherapy, hormonal therapy, or toxin therapy.
4. The method of claim 2 , wherein said second anti-cancer agent or treatment is given at the same time as said first antibody or antibody fragment.
5. The method of claim 2 , wherein said second anti-cancer agent or treatment is given before and/or after said first antibody or antibody fragment.
6. The method of claim 1 , wherein said glioma cell is a metastatic glioma cell, a multiply drug resistant glioma cell or a recurrent glioma cell.
7. The method of claim 1 , wherein said first antibody or antibody fragment is a single chain antibody or antibody fragment.
8. The method of claim 1 , wherein said first antibody or antibody fragment is a chimeric antibody a Fab fragment, or a murine antibody or antibody fragment.
9. The method of claim 1 , wherein said first antibody is an IgG, a humanized antibody, or a humanized IgG antibody.
10. The method of claim 1 , wherein said first antibody or antibody fragment further comprises an antitumor drug or label linked thereto.
11. The method of claim 10 , wherein said antitumor drug is linked to said first antibody or antibody fragment through a photolabile linker, or through an enzymatically-cleaved linker.
12. The method of claim 10 , wherein said antitumor drug is a toxin, a radioisotope, a cytokine, or an enzyme.
13. The method of claim 10 , wherein said label is a peptide tag, an enzyme, a magnetic particle, a chromophore, a fluorescent molecule, a chemilluminescent molecule, or a dye.
14. The method of claim 1 , wherein said first antibody or antibody fragment is conjugated to a liposome or nanoparticle.
15. The method of claim 1 , wherein said first antibody or antibody fragment results in the induction of cell death.
16. The method of claim 2 , wherein said second agent is an anti-VEGF antibody, an anti-EGFR antibody or an anti-c-Met antibody.
17. The method of claim 2 , wherein said second agent is a second anti-ELTD1 antibody, anti-Spondin-1 antibody or anti-SLIT3 antibody distinct first antibody or antibody fragment.
18. A method of treating glioma in a subject comprising administering to said subject a first antibody or antibody fragment that binds immunologically to ELTD1, Spondin-1 or SLIT3.
19. The method of claim 15 , wherein the induction of cell death involves antibody-dependent cell cytotoxicity or complement-mediated cytotoxicity.